Inactive Instrument

Highlights Stemline Therapeutics, Inc.

Equities

US85858C1071

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	Dec. 11	CI
Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	Dec. 08	CI
The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	Nov. 20	CI
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	23-10-30	CI
European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	23-09-20	CI
The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	23-05-25	CI
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting	23-05-09	CI
Stemline Therapeutics, Inc. Receives U.S. FDA Approval for ORSERDU	23-01-30	CI
The Menarini Group and Stemline Therapeutics to Present Additional Data from the Phase 3 EMERALD Study of Elacestrant, an Investigational Oral SERD, During the Upcoming San Antonio Breast Cancer Symposium	22-11-30	CI
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer	22-08-11	CI
Berlin-Chemie AG completed the acquisition of Stemline Therapeutics, Inc..	20-06-09	CI
Stemline Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Berlin-Chemie AG entered into an agreement to acquire Stemline Therapeutics, Inc. for approximately $610 million.	20-05-03	CI
Stemline Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-13	CI
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (Oral Presentation) and Multiple Myeloma at the 61st American Society of Hematology Annual Meeting	19-12-10	CI
Stemline Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Stemline Therapeutics Announces Three Elzonris Presentations, Including an Oral Presentation in Myelofibrosis, At Upcoming Ash Meeting	19-11-06	CI
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation from ESMO 2019 Congress	19-10-01	CI
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress	19-09-27	CI
Stemline Therapeutics To Seek Acquisitions	19-08-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Stemline Therapeutics, Inc.

Equities

US85858C1071

Highlights

Filters